Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis

Objective To examine the role of the variants of the PTPN22 and HLA – DRB1 genes as predictors of mortality in inflammatory polyarthritis (IP) and rheumatoid arthritis (RA). Methods Patients were recruited from a primary care–based inception cohort of patients with IP and were followed up prospectively. For patients who died, the cause and date of death was obtained. Cox proportional hazards regression models were used to assess the association of the HLA – DRB1 (including the shared epitope [SE]) and PTPN22 genes with the risk of death from all causes and from cardiovascular disease (CVD) and to assess the interactions between SE, smoking, and anti–cyclic citrullinated peptide (anti‐CCP) status, adjusted by age at symptom onset and sex. Results DNA samples were available from 1,022 IP patients. During followup, 751 of them (74%) satisfied the American College of Rheumatology 1987 criteria for RA, and 242 of them (24%) died. Carriage of 2 copies of SE alleles predicted death from all causes (hazard ratio [HR] 1.57 [95% confidence interval (95% CI) 1.1–2.2]) and from CVD (HR 1.68 [95% CI 1.1–2.7]). This effect was most marked for individuals with the HLA – DRB1 * 01 /* 04 combination. An interaction of smoking, SE alleles, and anti‐CCP antibodies was observed and was associated with the greatest risk of death from CVD (HR 7.81 [95% CI 2.6–23.2]). No association of the PTPN22 gene with mortality was detected. Conclusion SE alleles, particularly compound heterozygotes, are associated with death from all causes and from CVD, independently of autoantibody status. However, the combination of SE, smoking, and anti‐CCP antibodies is associated with a high risk of premature death in patients with IP and RA, which raises the possibility of a targeted strategy to prevent CVD in these patients.

1. 1.

   Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol. 2002;14:115-20.

   Not in our library10.1097/00002281-200203000-00007 (opens in a new tab)

2. 2.

   Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.

   Not in our library10.1056/nejm199704033361401 (opens in a new tab)

3. 3.

   Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562-71.

   Not in our library

4. 4.

   Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care–based inception cohort. Arthritis Rheum. 2005;52:2293-9.

   Not in our library10.1002/art.21204 (opens in a new tab)

5. 5.

   Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402-11.

   Not in our library10.1002/art.20853 (opens in a new tab)

6. 6.

   Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997;24:445-51.

   Not in our library

7. 7.

   Thomson W, Harrison B, Ollier B, Wiles N, Payton T, Barrett J, et al. Quantifying the exact role of HLA–DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum. 1999;42:757-62.

   Not in our library10.1002/1529-0131(199904)42:4<757::aid-anr20>3.0.co;2-x (opens in a new tab)

8. 8.

   Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths CE, et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 2005;52:1694-9.

   Not in our library10.1002/art.21049 (opens in a new tab)

9. 9.

   Wesoly J, van der Helm-van Mil AH, Toes RE, Chokkalingam AP, Carlton VE, Begovich AB, et al. Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort. Arthritis Rheum. 2005;52:2948-50.

   Not in our library10.1002/art.21294 (opens in a new tab)

10. 10.

    Hedger SC, Macardle P, Bond MJ, Ahern MJ, Smith MD, Roberts-Thomson PJ. Shared rheumatoid epitope as a risk factor in determining outcome in rheumatoid arthritis. Aust N Z J Med. 1999;29:234-8.

    Not in our library10.1111/j.1445-5994.1999.tb00689.x (opens in a new tab)

11. 11.

    Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum. 2004;50:400-12.

    Not in our library10.1002/art.20006 (opens in a new tab)

12. 12.

    Harrison B, Thomson W, Symmons D, Ollier B, Wiles N, Payton T, et al. The influence of HLA–DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum. 1999;42:2174-83.

    Not in our library10.1002/1529-0131(199910)42:10<2174::aid-anr19>3.0.co;2-g (opens in a new tab)

13. 13.

    Turesson C, Schaid DJ, Weyand CM, Jacobsson LT, Goronzy JJ, Petersson IF, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther. 2005;7:R1386-93.

    Not in our library10.1186/ar1837 (opens in a new tab)

14. 14.

    Weyand CM, Xie C, Goronzy JJ. Homozygosity for the HLA–DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J Clin Invest. 1992;89:2033-9.

    Not in our library10.1172/jci115814 (opens in a new tab)

15. 15.

    Gorman JD, David-Vaudey E, Pai M, Lum RF, Criswell LA. Particular HLA–DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum. 2004;50:3476-84.

    Not in our library10.1002/art.20588 (opens in a new tab)

16. 16.

    Wordsworth P, Pile KD, Buckely JD, Lanchbury JS, Ollier B, Lathrop M, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet. 1992;51:585-91.

    Not in our library

17. 17.

    MacGregor A, Ollier W, Thomson W, Jawaheer D, Silman A. HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol. 1995;22:1032-6.

    Not in our library

18. 18.

    Mattey DL, Dawes PT, Clarke S, Fisher J, Brownfield A, Thomson W, et al. Relationship among the HLA–DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum. 2002;47:403-7.

    Not in our library10.1002/art.10514 (opens in a new tab)

19. 19.

    Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006;54:1117-21.

    Not in our library10.1002/art.21739 (opens in a new tab)

20. 20.

    Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Epidemiological Investigation of Rheumatoid Arthritis Study Group, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38-46.

    Not in our library10.1002/art.21575 (opens in a new tab)

21. 21.

    Soderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol. 2004;33:185-8.

    Not in our library10.1080/03009740310004856 (opens in a new tab)

22. 22.

    Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004;63:1085-9.

    Not in our library10.1136/ard.2003.016808 (opens in a new tab)

23. 23.

    Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis. 2005;64:1744-9.

    Not in our library10.1136/ard.2004.033571 (opens in a new tab)

24. 24.

    Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis. 1990;49:980-2.

    Not in our library10.1136/ard.49.12.980 (opens in a new tab)

25. 25.

    Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis: results from a nationwide study of disease-discordant twins. Arthritis Rheum. 1996;39:732-5.

    Not in our library10.1002/art.1780390504 (opens in a new tab)

26. 26.

    Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care–based incident case–control study in Norfolk, England. Arthritis Rheum. 1997;40:1955-61.

    Not in our library10.1002/art.1780401106 (opens in a new tab)

27. 27.

    Gerli R, Sherer Y, Vaudo G, Schillaci G, Gilburd B, Giordano A, et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci. 2005;1051:281-90.

    Not in our library10.1196/annals.1361.069 (opens in a new tab)

28. 28.

    Goodson NJ, Silman AJ, Pattison DJ, Lunt M, Bunn D, Luben R, et al. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford). 2004;43:731-6.

    Not in our library10.1093/rheumatology/keh161 (opens in a new tab)

29. 29.

    Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol. 1994;33:735-9.

    Not in our library10.1093/rheumatology/33.8.735 (opens in a new tab)

30. 30.

    Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol. 1986;25:206-9.

    Not in our library10.1093/rheumatology/25.2.206 (opens in a new tab)

31. 31.

    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.

    Not in our library10.1002/art.1780310302 (opens in a new tab)

32. 32.

    International classification of diseases, ninth revision. 1977.

    Not in our library

33. 33.

    International statistical classification of diseases and related health problems, tenth revision. 1994.

    Not in our library

34. 34.

    Stata statistical software: release 9.0. 2003.

    Not in our library

35. 35.

    Cheung NT, Dawes PT, Poulton KV, Ollier WE, Taylor DJ, Mattey DL. High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol. 2000;27:882-7.

    Not in our library

36. 36.

    Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Vidan J, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003;114:647-52.

    Not in our library10.1016/s0002-9343(03)00133-5 (opens in a new tab)

37. 37.

    Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101:2883-8.

    Not in our library10.1161/01.cir.101.25.2883 (opens in a new tab)

38. 38.

    Jonasson L, Eriksson T, Dahlen GH, Lindblom B. Lipoprotein(a) and HLA-DRB1 and -DQB1 genes in coronary artery disease. Atherosclerosis. 1997;133:111-4.

    Not in our library10.1016/s0021-9150(97)00101-9 (opens in a new tab)

39. 39.

    Hauser ER, Crossman DC, Granger CB, Haines JL, Jones CJ, Mooser V, et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. Am J Hum Genet. 2004;75:436-47.

    Not in our library10.1086/423900 (opens in a new tab)

40. 40.

    Samani NJ, Burton P, Mangino M, Ball SG, Balmforth AJ, Barrett J, et al. A genomewide linkage study of 1,933 families affected by premature coronary artery disease: the British Heart Foundation (BHF) Family Heart Study. Am J Hum Genet. 2005;77:1011-20.

    Not in our library10.1086/498653 (opens in a new tab)

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.